Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
PM1183 plus doxorubicin shows interesting activity in small cell lung cancer

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 12.06.15
Views: 2193
Rating:

Dr Emiliano Calvo - START Madrid, Madrid, Spain

Dr Calvo talks to ecancertv at ASCO 2015 about data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with doxorubicin in second line therapy in patients with small cell lung cancer (SCLC)

The treatment induced objective responses in 67% of the patients, including 10% of them where all signs of cancer disappeared.

Every patient with SCLC denominated primary chemotherapy-sensitive (their chemotherapy-free interval is more than 90 days) responded to treatment, including 18% of complete responses.

In primary chemotherapy-resistant patients, where cancer was progressing within 90 days or less of previous chemotherapy, a remarkable 30% achieved a response.

Notably, the treatment resulted in durable responses, with an overall progression-free survival of 4.6 months, which was 3.6 months in resistant patients.

The most common adverse drug reaction was reversible myelosuppresion but no cardiotoxicity or drug-related deaths were observed.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation